Scarica l'app Stockscreener
17.28
1.50%
-0.35
Precedente Chiudi:
$17.63
Aprire:
$17.83
Volume 24 ore:
45,598
Relative Volume:
0.99
Capitalizzazione di mercato:
$539.85M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.66%
1M Prestazione:
-5.10%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.12
$18.42
Intervallo di 1 settimana:
$17.20
$20.85
Portata 52W:
$17.04
$24.03
Evommune Inc Stock (EVMN) Company Profile
Nome
Evommune Inc
Settore
Industria
Telefono
(650) 223-7745
Indirizzo
1841 PAGE MILL RD, PALO ALTO
Confronta EVMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
17.12 | 555.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.69 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
738.21 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.77 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.23 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
199.55 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Iniziato | Evercore ISI | Outperform |
| 2025-12-01 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-01 | Iniziato | William Blair | Outperform |
Evommune Inc Borsa (EVMN) Ultime notizie
Silicon Valley biotech firm expands to 43,000 square feet after going public - The Business Journals
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential - TipRanks
These Bay Area companies are IPO contenders in 2026 - The Business Journals
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks
CEO Pena Surrenders 28,138 Of Evommune Inc [EVMN] - TradingView — Track All Markets
Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets
EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets
Evommune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
EVMN: IPO proceeds and licensing revenue strengthen position ahead of key 2026 clinical readouts - TradingView — Track All Markets
Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat
Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech
Evommune, Inc. (EVMN) analyst ratings, estimates and forecasts - Yahoo Finance UK
Evommune (NYSE:EVMN) Upgraded at Zacks Research - Defense World
Evommune (EVMN) Competitors and Alternatives 2025 - MarketBeat
Evommune (NYSE:EVMN) Research Coverage Started at Evercore ISI - Defense World
Evommune (NYSE:EVMN) Shares See Activity on Sector Research Shift - Kalkine Media
Evommune (NYSE:EVMN) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Evommune initiated with an Outperform at William Blair - MSN
Evommune initiated with an Overweight at Cantor Fitzgerald - MSN
Evommune, Inc. (EVMN) options chain - Yahoo Finance UK
Evommune, Inc.: Revenue and Earnings Analysts Forecasts Revisions | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Target Price Consensus and Analysts Recommendations | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Dividend historical data and projections - marketscreener.com
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Leerink Partners - MarketBeat
Evommune initiated with an Overweight at Morgan Stanley - MSN
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential - Investing.com Australia
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Leerink Partners initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
Evommune, Inc. (EVMN) Stock Forum & Discussion - Yahoo! Finance Canada
Cantor Fitzgerald initiates Evommune stock with Overweight rating By Investing.com - Investing.com South Africa
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential By Investing.com - Investing.com South Africa
Leerink Partners initiates coverage on Evommune stock with Outperform rating - Investing.com Nigeria
Evommune initiated with an Outperform at Evercore ISI - MSN
Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales - Benzinga
EVMN Analyst Forecasts - Quiver Quantitative
This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
William Blair Initiates Coverage on Evommune With Outperform Rating - marketscreener.com
Evercore ISI Initiates Coverage on Evommune With Outperform Rating, $40 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Coverage on Evommune With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates Evommune stock with Overweight rating - Investing.com
Leerink Partners Initiates Coverage on Evommune With Outperform Rating, $42 Price Target - marketscreener.com
Morgan Stanley Initiates Evommune at Overweight With $36 Price Target - marketscreener.com
William Blair initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
William Blair initiates coverage on Evommune stock with Outperform rating - Investing.com
Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential - TipRanks
Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership - TipRanks
Morgan Stanley initiates Evommune stock with Overweight rating on inflammation pipeline - Investing.com Australia
What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research
Evommune Inc. (EVMN) Price Book Value - Zacks Investment Research
Evommune Inc Azioni (EVMN) Dati Finanziari
Non sono disponibili dati finanziari per Evommune Inc (EVMN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):